

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5923361

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PHARMASURGICS IN SWEDEN AB	10/02/2012
RECEIVING PARTY DATA	
Name:	PERGAMUM AB
Street Address:	KISP, FOGDEVRETEN 2
City:	SOLNA
State/Country:	SWEDEN
Postal Code:	171 65
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16555708
CORRESPONDENCE DATA	
Fax Number:	(617)607-9200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6174496500
Email:	cgiordani@mccarter.com
Correspondent Name:	MEI BAI, PH.D.
Address Line 1:	265 FRANKLIN STREET
Address Line 2:	MCCARTER ENGLISH LLP
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	128731-00104
NAME OF SUBMITTER:	MEI BAI, PH.D.
SIGNATURE:	/Mei Bai/
DATE SIGNED:	01/22/2020
Total Attachments: 8	
source=128731_Pharmasurgics_to_Pergamum#page1.tif	
source=128731_Pharmasurgics_to_Pergamum#page2.tif	
source=128731_Pharmasurgics_to_Pergamum#page3.tif	
source=128731_Pharmasurgics_to_Pergamum#page4.tif	
source=128731_Pharmasurgics_to_Pergamum#page5.tif	

source=128731_Pharmasurgics_to_Pergamum#page6.tif
source=128731_Pharmasurgics_to_Pergamum#page7.tif
source=128731_Pharmasurgics_to_Pergamum#page8.tif

ASSIGNMENT

THIS ASSIGNMENT, by Pharmasurgics in Sweden AB a corporation duly organized under and pursuant to the laws of Sweden and having its principal place of business at Arvid Walkgrens Backe 20, 413 46 Göteborg, Sweden (hereinafter referred to as "the Assignor"), witnesseth:

WHEREAS, the Assignor is the owner of certain new and useful improvements set forth in 1)-8);

- 1) U.S. Patent No. 7,253,143, entitled Peptides Based on the Sequence of Human Lactoferrin and Their Use, by Assignment recorded in the U.S. Patent and Trademark Office on Reel 018685, Frame 0271;
- 2) U.S. Patent No. 7,803,757, entitled Peptides Based on the Sequence of Human Lactoferrin and Their Use, by Assignment recorded in parent patent U.S. Patent No. 7,253,143 in the U.S. Patent and Trademark Office on Reel 018685, Frame 0271;
- 3) U.S. Patent No. 7,427,589, entitled Novel Use of Cytokine Inhibitors, by Assignment recorded in the U.S. Patent and Trademark Office on Reel 018685, Frame 0259;
- 4) U.S. Patent No. 7,994,116, entitled Methods for Reduction of Adhesion Formation Using Cytokine Inhibitors, by Assignment recorded in parent patent U.S. Patent No. 7,427,589 in the U.S. Patent and Trademark Office on Reel 018685, Frame 0259;
- 5) U.S. Patent No. 7,928,185, entitled Synthetic Arginine Substituted Peptides and Their Use, by Assignment recorded in the U.S. Patent and Trademark Office on Reel 022185, Frame 0556;
- 6) U.S. Patent Application Serial No. 13/089,680, entitled Synthetic Arginine Substituted Peptides and Their Use, by Assignment recorded in parent patent U.S. Patent No. 7,928,185 in the U.S. Patent and Trademark Office on Reel 022185, Frame 0556;
- 7) U.S. Patent Application Serial No. 13/143,675, entitled New Pharmaceutical Compositions, by Assignment recorded in the U.S. Patent and Trademark Office on Reel 026773, Frame 0231;
- 8) U.S. Patent Application Serial No. 12/717,103, entitled Novel Use of Cytokine Inhibitors, by Assignment recorded in the U.S. Patent and Trademark Office on Reel 018685, Frame 0262;

WHEREAS, Pergamum AB, a corporation duly organized under and pursuant to the laws of Sweden and having its principal place of business at Benväktsvägen 12, 171 46 Solna, Sweden (hereinafter referred to as "the Assignee"), is desirous of acquiring, and does hereby acquire, the entire right, title, and interest in and to said patents and applications.


NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to the above-mentioned patents and applications, and releases and extensions of said Letters Patent or Patents or Patents issuing from said applications, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own use and behoof and the use and behoof of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents or Patents issuing from said applications may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, the Assignor is the sole and lawful owner of the entire right, title, and interest in and to said patents and applications, and that the same are unencumbered, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said patents and applications, or any reissue or extension of any Letters Patent or Patents or Patents issuing from said applications obtained or to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement, and defense of Letters Patent or Patents or Patents issuing from said applications, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

Pharmasurgics in Sweden AB

Date: 2 Oct 2012

By: 

Title: GROUP PRESIDENT

Registration number	
556759-9203	
Date of registration of the company	Date of registration of current report
2008-06-18	2009-02-12
Document created on	Page
2012-10-02 14:24	1 (2)

Registration number: 556759-9203
Business name: Patagonia AB
Address: Gårdsplan 12
171 4P JÖKINA
Registered office: Solna
Note:

The company is registered as a private limited liability company

THE COMPANY WAS FORMED
2008-06-18

SHARE CAPITAL

Share capital: SEK 14,000,000
Min.: SEK 8,000,000
Max.: SEK 32,000,000
Number of shares: 14,000,000
Min.: 8,000,000
Max.: 32,000,000

BOARD MEMBER, CHAIR OF THE BOARD

621112 Stierke, Torbjörn, Östrapvej 1, DK-3483 RØNDEBØSCAC,
DANMARK

BOARD MEMBERS

420524-2058 Bogentoft, Omay Boris, Alstorsikavägen 156,
105 72 VÅSTENBY
600421-6203 Casserotest, Jan Gunnar, Teaterlidens väg 4, 811 95 STAVSÖ
620425-1113 Linder, Göran Henrik, Sönnarvägen 12, 163 60 TÄBY
450703-1125 Petersson, Nils Göran, Lutsengatan 7, 5 Str,
113 20 STOCKHOLM
520629-5134 Rydmark, Erik Bertil, 4 Lighthouse Lane,
06870 OLD GDERWATER, USA

DEPUTY BOARD MEMBERS

741221-1976 Gunnarsson, Per Andreas, Hvalensöyvänen 94, 585 03 LERKUNING
602776-4936 Linder, Björn Erik, Essinge Högväg 39, 113 49 STOCKHOLM
450430-2760 Tabbie, Mona Lisbet, Odengatan 22, 1302,
113 22 STOCKHOLM

MANAGING DIRECTOR

Registration number 556759-9203	
Date of registration of the company 2008-06-18	Date of registration at current name 2009-02-12
Document created on 2012-10-02 16:24	Page 2 (2)

65041-1254 Gården, Lasse Gården, Fjellvågen 41, 141 43 BUCKINGE

DEPUTY MANAGING DIRECTORS

700227-0424 Wenuberg, Gicika Maria, Fjellvågen 14 3tr, 141 47 BUCKINGE

AUDITORS

556271-5508 Eklund AB, 113 79 STOCKHOLM

Represented by: 51002-660

PRINCIPALLY RESPONSIBLE AUDITOR

651009-6692 Stromberg, Alf Thomas, c/o Deloitte AB, 113 79 STOCKHOLM

SIGNATORY POWER

The board of directors is entitled to sign on behalf of the company.

Signatory power by any one of

Björke, Torbjörn

Bogertoft, Gunnar Björn

In combination with any one of

Cassengren, Jan Gunnar

Linder, Göran Nils

Torilsson, Göran Göran

Sydeberg, Erik Erik

Furthermore, the Managing Director, on his normal business activities, is also entitled to sign on behalf of the company.

ARTICLES OF ASSOCIATION

Date of the latest change: 2011-06-22

FINANCIAL YEAR

Registered financial year: 2011 - 2011

Latest annual report submitted covers financial

period 2011/2011-2011/2011

DATE OF REGISTRATION OF CURRENT AND PREVIOUS COMPANY NAMES

2009-02-12 Pergamon AB

2008-06-18 KewCo 2129 Sweden AB

*** The above information is an extract from the Trade and Industry Register Bolagsverket, the Swedish Companies Registration Office ***

Bolagsverket

851 81 Järnvägs

060 70 40 00

Bolagsverket@bolagsverket.se

www.bolagsverket.se

Registration number 356664-7839	
Date of registration of the company 2004-08-11	Date of registration of latest name 2005-03-15
Document created on 2012-10-02 16:23	Page 1 (2)

Registration number: 356664-7839
Business name: PharmASuisse In Sweden AB
Address:
Arvid Wallgrens Gata 20
411 46 GÖTEBORG
Registered office:
Sweden

The company is registered as a private limited liability company

THE COMPANY WAS FORMED
2004-04-21

SHARE CAPITAL

Share capital...: SEK 783,149 Min.: SEK 600,000
Max.: SEK 2,400,000
Number of shares: 783,149 Min.: 600,000
Max.: 2,400,000

BOARD MEMBER, MANAGING DIRECTOR

70512-1706 Mahlman, Margit, Linnégatan 39, 413 06 GÖTEBORG

BOARD MEMBER, CHAIR OF THE BOARD

160276-6936 Clander, Björn Erik, Essinge Högväg 34, 112 65 STOCKHOLM

BOARD MEMBERS

700227-0414 Wennerberg, Ulrika Maria, Forsellvägen 14, 141 47 HÖDINGE

SPECIALLY AUTHORIZED SIGNATORIES

650417-1154 Ekblom, Jonas Göran, Tellusvägen 41, 163 43 SPÅNGA

AUDITORS

556271-5309 Deloitte AB, Roburstran 11, 113 78 STOCKHOLM
Represented by: 750917-5698

PRINCIPALLY RESPONSIBLE AUDITOR

750827-5695 Ståhlberg, Carl Jonas Stefan, c/o Deloitte AB,
111 78 STOCKHOLM

SIGNATORY POWER

Registration number	
556664-7839	
Date of registration of the company	Date of registration of current name
2004-08-11	2005-03-15
Document created on	Page
2012-10-02 16:23	2 (2)

The board of directors is authorized to sign on behalf of the company.
Signatory power is, at the same time, of

the board members
signatory power is, at the same time, of

the board members, in his formal capacity as a director,
is also authorized to sign on behalf of the company.

ARTICLES OF ASSOCIATION

Date of the latest change: 2011-05-16

FINANCIAL YEAR

Registered financial year: 01-01 - 12-31
Latest annual report submitted covers financial
period: 2011-01-01-2011-12-31

DATE OF REGISTRATION OF CURRENT AND PREVIOUS COMPANY NAMES

2005-03-15 PharmaSurgica AB Henden AB
2004-08-30 Pro forma Suuri AB
2004-08-11 Aktiebolaget Grundstenen 1928AB

*** The above information is an extract from the Trade and Company
Register Bolagsverket, the Swedish Companies Registration Office ***

Bolagsverket
451 91, Sundsvall
060 13 19 00
Bolagsverket.Tul.se@bolagsverket.se
www.bolagsverket.se

Fullmakt

Power of Attorney

Jonas Ekblom (personnummer 650417-1254), eller den han sätter i sitt ställe, ges härmed fullmakt att teckna Pergamum AB:s (organisationsnummer 556759-9203) firma på samtliga handlingar som rör överlåtelse av patent/patentansökningar från DermaGen AB (organisationsnummer 556655-4431) och PharmaSurgics In Sweden AB (organisationsnummer 556664-7839) till Pergamum AB.

Jonas Ekblom (PIN 650417-1254), or whoever he may appoint, is hereby given power of attorney to sign for Pergamum AB (CIN 556759-9203) on all documents regarding transfer of patents/patent applications from DermaGen AB (CIN 556655-4431) and PharmaSurgics In Sweden AB (CIN 556664-7839) to Pergamum AB.

Denna fullmakt gäller till och med den 31 december 2012 då den upphör automatiskt.

This power of attorney shall be valid until 31 December 2012 when it expires automatically.

Solna 2 October 2012



Torbjörn Bjerke

Göran Linder

Fullmakt

Power of Attorney

Jonas Ekblom (personnummer 650417-1254), eller den han sätter i sitt ställe, ges härmed fullmakt att teckna Pergamum AB:s (organisationsnummer 556759-9203) firma på samtliga handlingar som rör överlåtelse av patent/patentansökningar från DermaGen AB (organisationsnummer 556655-4431) och PharmaSurgics in Sweden AB (organisationsnummer 556664-7839) till Pergamum AB.


Jonas Ekblom (PIN 650417-1254), or whoever he may appoint, is hereby given power of attorney to sign for Pergamum AB (CIN 556759-9203) on all documents regarding transfer of patents/patent applications from DermaGen AB (CIN 556655-4431) and PharmaSurgics in Sweden AB (CIN 556664-7839) to Pergamum AB.

Denna fullmakt gäller till och med den 31 december 2012 då den upphör automatiskt.

This power of attorney shall be valid until 31 December 2012 when it expires automatically.

Solna 2 October 2012

Göran Linder



Göran Linder